Rare Lung Disease Company Draws Attention with Successful Phase 3 IPF Drug and Insider Trading Worth Millions

United Therapeutics Corp. (UTHR) reported that its inhaled treprostinil therapy Tyvaso met the primary endpoint in the Phase 3 TETON-1 trial for patients with idiopathic pulmonary fibrosis (IPF), delivering an approximately 130 mL improvement in forced vital capacity (FVC) over placebo. The study also showed a reduction in clinical worsening and significant benefits across multiple secondary endpoints. The company said no new safety signals emerged and plans to submit a supplemental New Drug Application to the U.S. FDA for the IPF indication by late summer 2026, requesting priority review.

On the same day, Chairman and CEO Martine Rothblatt and CFO James Edgemon, following pre-established Rule 10b5-1 trading plans, exercised stock options and sold nearly the same number of shares in the open market, realizing cash proceeds in the tens of millions of dollars. Both executives maintained substantial post-transaction ownership, according to the regulatory filing.

Recently, United Therapeutics received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for MiroLiver ELAP, an extracorporeal liver support device for acute liver failure. Last month, the company announced a $2 billion share repurchase program and a $1.5 billion accelerated share repurchase agreement. It is also set to release first-quarter 2026 financial results before the U.S. market opens on April 29, with investors focused on updates regarding its pipeline and capital allocation strategy.

United Therapeutics is a U.S. biotechnology company that develops and commercializes treatments for severe rare and chronic pulmonary diseases—including pulmonary arterial hypertension—and regenerative medicine-based organ replacement technologies. Its inhaled treprostinil formulation, Tyvaso, is the company’s flagship product. Therapies for rare lung disorders such as IPF and organ transplant alternatives are viewed as high-growth areas in the global pharmaceutical and biotech industry, driven by aging populations and rising demand for transplantable organs.